Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development of Radioligand Therapy-Responsive Syngeneic Prostate Models through Murine Prostate-Specific Membrane Antigen Point Mutation.

ACS pharmacology & translational science·2026
Same author

Radiopharmaceutical Therapy Meets Radiobiology: Implications for Trial Design and DNA Repair Inhibitor Combinations.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same author

Updates on radiotherapy-immunotherapy combinations: Proceedings of 8th Annual ImmunoRad Conference.

Oncoimmunology·2025
Same author

Methodology for comparing absorbed dose rate calculation algorithms in molecular radiotherapy dosimetry.

Physica medica : PM : an international journal devoted to the applications of physics to medicine and biology : official journal of the Italian Association of Biomedical Physics (AIFB)·2025
Same author

Oxaliplatin, ATR inhibitor and anti-PD-1 antibody combination therapy controls colon carcinoma growth, induces local and systemic changes in the immune compartment, and protects against tumor rechallenge in mice.

Journal for immunotherapy of cancer·2025
Same author

MHC-I-Driven Antitumor Immunity Counterbalances Low Absorbed Doses of Radiopharmaceutical Therapy.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2025

Related Experiment Video

Updated: May 30, 2025

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence
08:55

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

12.2K

Development of an in vivo ovarian cancer peritoneal carcinomatosis model for radioimmunotherapy testing.

Clara Diaz Garcia-Prada1, Salima Atis1, Jean-Pierre Pouget1

  • 1Institut de Recherche en Cancérologie de Montpellier (IRCM), INSERM U1194, Université de Montpellier, Institut régional du Cancer de Montpellier (ICM), Montpellier, France.

Methods in Cell Biology
|January 25, 2025
PubMed
Summary

Targeted radionuclide therapy (TRT) shows promise for treating ovarian cancer peritoneal carcinomatosis. This study developed a mouse model and demonstrated lutetium-177-labeled trastuzumab effectively targets and irradiates ovarian cancer cells.

Keywords:
Epithelial ovarian cancerHGSOCRadiopharmaceuticalsTargeted radionuclide therapy

More Related Videos

In vivo Imaging and Therapeutic Treatments in an Orthotopic Mouse Model of Ovarian Cancer
07:46

In vivo Imaging and Therapeutic Treatments in an Orthotopic Mouse Model of Ovarian Cancer

Published on: August 17, 2010

33.3K
Murine Experimental Model of Original Tumor Development and Peritoneal Metastasis via Orthotopic Inoculation with Ovarian Carcinoma Cells
08:17

Murine Experimental Model of Original Tumor Development and Peritoneal Metastasis via Orthotopic Inoculation with Ovarian Carcinoma Cells

Published on: December 9, 2016

10.5K

Related Experiment Videos

Last Updated: May 30, 2025

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence
08:55

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

12.2K
In vivo Imaging and Therapeutic Treatments in an Orthotopic Mouse Model of Ovarian Cancer
07:46

In vivo Imaging and Therapeutic Treatments in an Orthotopic Mouse Model of Ovarian Cancer

Published on: August 17, 2010

33.3K
Murine Experimental Model of Original Tumor Development and Peritoneal Metastasis via Orthotopic Inoculation with Ovarian Carcinoma Cells
08:17

Murine Experimental Model of Original Tumor Development and Peritoneal Metastasis via Orthotopic Inoculation with Ovarian Carcinoma Cells

Published on: December 9, 2016

10.5K

Area of Science:

  • Oncology
  • Radiotherapy
  • Molecular Imaging and Therapeutics

Background:

  • Ovarian cancer (OC) is a lethal gynecological malignancy often diagnosed at advanced stages with peritoneal carcinomatosis (PC).
  • Current treatments involving surgery and chemotherapy have high recurrence rates (70-90%), necessitating novel therapeutic strategies.
  • Targeted radionuclide therapy (TRT) offers a promising approach by delivering localized radiation to tumor cells.

Purpose of the Study:

  • To establish a preclinical model for ovarian cancer peritoneal carcinomatosis.
  • To evaluate the efficacy of targeted radionuclide therapy using lutetium-177-labeled trastuzumab in this model.
  • To demonstrate a method for monitoring treatment response in vivo.

Main Methods:

  • Developed an ovarian cancer peritoneal carcinomatosis model by grafting human SK-OV-3 cells into immunodeficient mice.
  • Labeled trastuzumab with lutetium-177 for targeted delivery to SK-OV-3 cell nodules.
  • Monitored the in vivo response to lutetium-177-trastuzumab targeted radionuclide therapy.

Main Results:

  • Successfully established a reproducible human ovarian cancer peritoneal carcinomatosis model in mice.
  • Demonstrated that lutetium-177-labeled trastuzumab specifically targets and irradiates SK-OV-3 tumor nodules.
  • Showcased the feasibility of monitoring TRT efficacy in vivo within this model.

Conclusions:

  • Targeted radionuclide therapy with lutetium-177-trastuzumab is a viable therapeutic strategy for ovarian cancer peritoneal carcinomatosis.
  • The developed preclinical model and labeling technique are adaptable for various human and mouse tumors.
  • TRT presents a potential alternative to conventional radiotherapy for managing disseminated ovarian cancer due to its multisite delivery capability.